SCHEMBL176969

SCHEMBL176969

CCCC(=O)c1ccc(O)cc1F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.54
HSD17B3 P37058 2/20 0.52
ALDH1A1 P00352 2/20 0.50
CHRNA7 P36544 1/20 0.50
HPGD P15428 1/20 0.50
ALOX15 P16050 1/20 0.50
TSHR P16473 1/20 0.50
RECQL P46063 1/20 0.50
HSD17B10 Q99714 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
HSP90AB1 P08238 1/20 0.49
KDM4E B2RXH2 1/20 0.44
MAPK1 P28482 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
ESRRG P62508 1/20 0.42
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17671231 0.87 HTT (0.69) HTTHSD17B3ALDH1A1CHRNA7HPGD
SCHEMBL177181 0.85 HSP90AB1 (0.67) HTTALDH1A1CHRNA7HSP90AB1MAPK1
SCHEMBL6944180 0.84 CES2 (0.57) ALDH1A1HPGDALOX15TSHRRECQL
SCHEMBL29688370 0.82 MEN1 (0.49) HTTHSD17B3ALDH1A1HPGDALOX15
SCHEMBL20134974 0.82 MEN1 (0.49) HTTHSD17B3ALDH1A1HPGDALOX15
SCHEMBL31166012 0.81 HTT (0.77) HTTHSD17B3ALDH1A1HPGDALOX15
SCHEMBL3662473 0.81 HTT (0.77) HTTHSD17B3ALDH1A1HPGDALOX15
SCHEMBL11900526 0.81 DGAT1 (0.56) HTTALDH1A1HPGDALOX15TSHR
Hydrochloric Acid SCHEMBL3323949 0.80 MAOB (0.54) HTTALDH1A1CHRNA7HSD17B10HSP90AB1
SCHEMBL7681705 0.79 CTSK (0.47) HTTALDH1A1CHRNA7HSP90AB1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008506-B2 Indazole compounds ASAHI KASEI PHARMA CORPORATION (JP) 2011-08-30 US disclosed
US-8008506-B2 Indazole compounds ASAHI KASEI PHARMA CORPORATION (JP) 2011-08-30 US disclosed
US-8008506-B2 Indazole compounds ASAHI KASEI PHARMA CORPORATION (JP) 2011-08-30 US disclosed
EP-2345644-A1 INDAZOLE COMPOUND Asahi Kasei Pharma Corporation (JP) 2011-07-20 EP disclosed
US-20100160256-A1 INDAZOLE COMPOUNDS ASAHI KASEI PHARMA CORPORATION (JP) 2010-06-24 US disclosed
US-20100160256-A1 INDAZOLE COMPOUNDS ASAHI KASEI PHARMA CORPORATION (JP) 2010-06-24 US disclosed
US-20100160256-A1 INDAZOLE COMPOUNDS ASAHI KASEI PHARMA CORPORATION (JP) 2010-06-24 US disclosed
WO-2010041569-A1 INDAZOLE COMPOUND 旭化成ファーマ株式会社 (JP) 2010-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160256-A1 INDAZOLE COMPOUNDS GPR119, ADRB1, ADRA1A HTT 3085/4885HSD17B3 95/4885ALDH1A1 131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.